Individual growth curves for both the primary NPS-treated tumors (black) and the re-challenge tumors (red) show that NPS-treated control and NPS-treated CD4-depleted mice (Fig 5A and 5B) were protected against tumor re-challenge or tumor growth was delayed, indicative of an ongoing anti-tumor immune response, while NPS-treated CD8-depleted mice (Fig 5C) have a tumor growth and survival profile similar to the naïve group. The gene discussed is CD4; the disease is neoplasm.